Innovative clinical trial designs with a patient-centered mission are crucial to advancing modern cancer care; the adaptive phase 2 umbrella study CTONG1702 provides one model for this new era of trial design.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Riudavets, M., Sullivan, I., Abdayem, P. & Planchard, D. ESMO Open 6, 100260 (2021).
Li, B. T. et al. N. Engl. J. Med. 386, 241–251 (2022).
Subbiah, V. Nat. Med. 29, 49–58 (2023).
Liu, S. Y. M. T. H. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02461-x (2023).
Redman, M. W. et al. Lancet Oncol. 21, 1589–1601 (2020).
Kim, E. S. et al. Clin. Cancer Res. 27, 2394–2399 (2021).
Cancer Discov. 13, 1279–1280 (2023).
Nabhan, C., Klink, A. & Prasad, V. JAMA Oncol. 5, 781–783 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.B.G. reports research funding from AstraZeneca, Boehringer Ingelheim and Mirati, and consulting for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Takeda, Janssen, Summit Therapeutics, Merck and Regeneron. M.J.G. declares no competing interests.
Rights and permissions
About this article
Cite this article
Grant, M.J., Goldberg, S.B. Precise, pragmatic and inclusive: the modern era of oncology clinical trials. Nat Med 29, 1908–1909 (2023). https://doi.org/10.1038/s41591-023-02466-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02466-6